All In Biotech

NDA 018609 · Baxter Hlthcare

Heparin Sodium 2,000 Units and Sodium Chloride 0.9% In Plastic Container

Heparin Sodium · Injection

Last checked: Nov 19, 2026Latest source record: Jan 3, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Apr 28, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,126

334 Phase 3, 112 recruiting

FAERS reports

14,076

11,068 serious, 2,654 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 3, 2022.

Heparin Sodium in Sodium Chloride Injection at a concentration of 2 units/mL is indicated as an anticoagulant to maintain catheter patency. Heparin Sodium in Sodium Chloride Injection at a concentration of 2 units/mL is indicated as an anticoagulant to maintain catheter patency. ( 1 )

Mechanism: Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 28, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · HEPARIN SODIUM 2,000 UNITS/1000ML · INJECTABLE, INJECTION · Prescription
  • HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · HEPARIN SODIUM 200 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · HEPARIN SODIUM 500 UNITS/100ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · HEPARIN SODIUM 200 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Heparin" as an intervention, any sponsor and status, largest first.

All 1,126 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • heparin-induced thrombocytopenia1,293
  • drug ineffective1,046
  • off label use788
  • nausea754
  • drug hypersensitivity643
  • vomiting621
  • hypotension572
  • dyspnoea558
  • pulmonary embolism520
  • sepsis503
  • pyrexia499
  • anaemia488

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004464
2005225
2006189
2007127
20081,029
2009247
2010472
2011403
2012356
2013329
2014276
2015367
2016402
2017528
2018642
2019801
2020706
2021976
20221,142
20231,254
20241,028
2025998
20261,115

Recalls

4 FDA enforcement reports for this application.

  • Aug 1, 2024 · Class I · Ongoing

    Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

  • Jun 3, 2015 · Class II · Terminated

    Subpotent Drug; out of specification results for heparin raw material

  • Oct 30, 2014 · Class II · Terminated

    Subpotent Drug: Heparin raw material was found to have low potency

  • May 21, 2013 · Class II · Terminated

    Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred...

Shortages

FDA's drug shortage list.

  • Current · updated Nov 3, 2026

    Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03). Demand increase for the drug

  • Current · updated Nov 18, 2026

    Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,572 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Heparin Sodium 5,000 Units and Sodium Chloride 0.9% In Plastic Container, Heparin Sodium 1,000 Units and Sodium Chloride 0.9% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.